Skip to main content

During clinical trials, the most frequently reported adverse event in the BenzaClin (clindamycin and benzoyl peroxide) treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the BenzaClin (clindamycin and benzoyl peroxide) and vehicle groups.

Local Adverse Events - all causalities in > /= 1% of patients

  BenzaClin
n = 420
Vehicle
n = 168
Application site reaction 13 (3%) 1 ( < 1%)
Dry skin 50 (12%) 10 (6%)
Pruritus 8 (2%) 1 ( < 1%)
Peeling 9 (2%) -
Erythema 6 (1%) 1 ( < 1%)
Sunburn 5 (1%) -

The actual incidence of dry skin might have been greater were it not for the use of a moisturizer in these studies.

Anaphylaxis, as well as allergic reactions leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.